<DOC>
	<DOCNO>NCT00151008</DOCNO>
	<brief_summary>To determine bexarotene gel NBUVB phototherapy effective placebo plus NBUVB moderate severe plaque-type psoriasis .</brief_summary>
	<brief_title>Bexarotene With Narrow-Band UVB Psoriasis</brief_title>
	<detailed_description>Subjects apply active gel placebo target lesion side body blind manner . They start three time week increase daily even twice day regimen tolerate . After 2 week application , NBUVB add treatment regimen ( whole body , three time week ) . Total study time 10 week .</detailed_description>
	<mesh_term>Psoriasis</mesh_term>
	<mesh_term>Bexarotene</mesh_term>
	<criteria>Inclusion Criteria Patient must male female age 18 year old Patient must moderate severe psoriasis vulgaris least 3 % body surface area involvement Patient must fail prior topical therapy Patient must willing minimize sun exposure , use sun blocker deem necessary Investigator avoid use tan booth ultraviolet ( UV ) light source Women childbearing potential must negative urine ßHCG pregnancy test sensitivity least 50 mIU/mL within seven day prior start study gel repeat every four week patient remain study gel . All female childbearing potential must agree use 2 effective contraceptive method remain sexually abstinent one month prior initiation study drug , entire study period , one month last application Targretin® gel 1 % . Acceptable method birth control include : condom spermicide ; diaphragm spermicide ; cervical cap spermicide ; spermicidal sponge ; intrauterine device ( IUD ) , oral contraceptive , DepoProvera ; contraceptive implant ; vasectomy ; abstinence . Male patient must agree use condom sexual partner childbearing potential entire period treatment least one month treatment discontinue . Patients sexually active use contraception , must agree use approve method contraception ( describe ) become sexually active study Exclusion Criteria Failure understand consent form Inability comply protocol requirement Pregnancy Inadequate birth control method Lactation Contraindication use topical retinoids Concomitant psoriasis therapy except emollient OTC shampoo Systemic psoriasis therapy , systemic Vitamin A dose &gt; 15,000IU/day , PUVA , ( psoralen plus ultraviolet A irradiation ) , UVB , topical psoriasis therapy ( emollient OTC shampoo ) , retinoid class drug investigational drug within past 1 month Current skin cancer History previous melanoma History skin sensitizing disease ( SLE ) Concurrent medical illness would make participation clinical trial illadvised Patient unwilling unable avoid prolong exposure sun UV light source</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2008</verification_date>
	<keyword>psoriasis</keyword>
	<keyword>bexarotene</keyword>
	<keyword>narrow band</keyword>
	<keyword>UVB</keyword>
</DOC>